Table 2.
Description of Potential Prognostic lncRNA Markers in Colorectal Cancer
| Type of cancer | Biological (Ref) | Clinical (Ref) |
|---|---|---|
| Hepatocellular carcinoma | Promoting cell invasion and metastasis through inhibiting miR-129-5p (Zhang et al., 2017). | Potential candidate for HCC diagnosis and treatment (Zhang et al., 2017). |
| Increasing cell proliferation and migration, decreasing apoptosis (Wen et al., 2016). | Candidate biomarker for HCC therapeutic strategies (Wen, Xu et al. 2016). | |
| Potential diagnostic tool or therapeutic target for HCC (Zhang et al., 2016). | ||
| Gastric cancer | Promoting cell proliferation, migration and invasion through regulating CDKN1A (Bi et al., 2017). | Potential diagnostic marker of gastric cancer (Bi et al., 2017). |
| Colorectal cancer | Promoting cell invasion, metastatic potential and drug resistance through c-Myc(Qiao et al., 2017). | Potential candidate biomarker for CRC (Qiao et al., 2017). |
| Increasing cell proliferation (Qiao et al., 2017). | ||
| Breast cancer | Correlating with clinical characteristics and as a biomarker for breast cancer (Sarrafzadeh et al., 2017). | |
| Prostate cancer | Promoting proliferation, migration and invasion, inhibiting apoptosis (Xu et al., 2017). | As a predictive biomarker (PCAT-1) was applied in PARP1 inhibitor therapy of patients (Prensner et al., 2014). |
| Increasing cell proliferation through modulating cMyc function (Evans et al., 2014). | As key aspects of disease biology and clinically important biomarkers (Prensner et al., 2011; Prensner et al., 2011). | |
| Acting as oncogenic lncRNA in prostatecancer proliferation through cMyc(Prensner, Chen et al., 2014). | ||
| Regulating BRCA2 levels (Prensner et al., 2011, Prensner et al., 2011) and homologous recombination (Prensner et al., 2014). | ||
| Lung cancer | Promoting cell proliferation, migration and invasion (Zhao et al., 2015). | Potential therapeutic target (Zhao et al., 2015). |
| Bladder cancer | Decreasing cell proliferation and increasing cell apoptosis (Liu et al., 2015). | Acting as a biomarker for predicting bladder cancer (Liu et al., 2015; Xu et al., 2017). |
| Cervical cancer | Increasing cell proliferation, metastasis and invasion (Ma et al., 2018). | |
| Osteosarcoma | Increasing cell proliferation, migration and invasion by interacting with EZH2 and repressing p21 gene (Huang et al., 2018). | |
| Eusophagus squamous cell carcinoma | Promoting cancer cell proliferation and growth (Zhen., 2018). | |
| Multiple myeloma | Correlating with the clinicopathologic features and acting as a potential diagnostic target (Shen et al., 2017). | |
| Extrahepatic Cholangiocarcinoma | Promoting cell proliferation and inducing cell apoptosis. Acting as a competing endogenous RNA (ceRNA) against miR-122. | |
| Regulating WNT1 expression via miR-122 (Zhang et al., 2017). |
CRC, colorectal cancer; EMT, Epithelial-mesenchymaltransition; lincRNA, long intergenic non-coding RNA, MM, Multiple myeloma; ECC, Extrahepatic cholangiocarcinoma; PARP-1, Poly [ADP-ribose] polymerase 1; NSCLC, Non-small-cell lung carcinoma.